After hitting a wall with the FDA last year, Novo Nordisk has picked up backing from European drug reviewers for its novel ...

As recovery efforts at the North Carolina plant hit by Hurricane Helene move at an “encouraging pace,” Baxter International ...

Novo Holdings is encountering more resistance as it aims to close its $16.5 billion acquisition of pharma manufacturing giant ...

Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...

Eli Lilly is making a series of investments in China to support its manufacturing and R&D operations. Gilead Sciences has ...

As a host of generics circle the gates, Novartis has lost another bid to waylay MSN Pharmaceuticals’ copycat of the Swiss ...

As the first treatment cleared by the FDA for Demodex blepharitis, an eye disease estimated to affect 25 million people in ...

After Viatris’ CEO earlier this year promised to be “opportunistic” about future business development moves, the company is ...

AbbVie made history in 2015 with its Parkinson’s disease infusion pump therapy Duopa, kicking off a trend of delivery system ...

While radiopharmaceuticals have attracted significant interest in recent years thanks to their cancer-fighting prowess, the ...

OmniaBio, a CDMO focused on cell and gene therapies, debuted a new manufacturing facility it claims to be the largest of its ...

With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...